Insilico Medicine has partnered with Inimmune to utilize Chemistry42, Insilico’s generative AI technology, to accelerate the discovery of immunotherapeutics. Chemistry42 enables the rapid generation and screening of drug molecules with customized properties, improving efficiency in drug discovery. Inimmune benefited from the platform’s ability to generate novel compounds and evaluate key attributes, leading to enhanced research strategies. The collaboration has already resulted in improved hit series and optimized compounds for further development. By leveraging AI-driven platforms like Chemistry42, pharmaceutical research can be streamlined, leading to the discovery of successful therapeutic candidates. This partnership highlights the transformative impact of advanced computational tools in drug development.
Source link
Insilico Medicine partners with Inimmune to advance immunotherapeutic discovery
